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Toxoplasmosis is caused by an obligatory intracellular protozoon. It causes a wide range of diseases with toxoplasma 
encephalitis commonly encountered in HIV/AIDS patients. This work was carried out to determine the seroprevalence of 
toxoplasma antibodies (IgM and IgG) in HIV/AIDS patients attending the Yaoundé University Teaching Hospital (UTH) in 
Cameroon. Sera were collected from 133 HIV/AIDS patients at the out-patient department and the ELISA technique was 
employed serologically to determine toxoplasma antibodies.  Of the 133 patients 83 (62.4%) were females and 59 (37.6%) 
were males; ninety three (69.9%) were positive for toxoplasma antibodies. Fourteen (10.8%) of the 93 of seropositive patients 
presented with both IgG and IgM-antibodies in their sera while fifty six (42.1%) and 8 (6.0%) were only sero-positive for 
toxoplasma IgG or IgM-antibody respectively 
This rate of infection was not dependent on the patient’s sex or age (X2=11.49, P>0.05).  The data provides enough evidence 
to conclude that 64.7% of the positive cases were due to reactivated infection.  
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INTRODUCTION 
Toxoplasmosis is caused by an obligatory 
intracellular protozoan; Toxoplasma gondii of 
worldwide distribution (1). It has gradually evolved 
over the pass decades to be among the most 
common opportunistic diseases in HIV/AIDS in 
developing countries (2). The prevalence of sero-
positivity for antibodies against Toxoplasma gondii 
has been estimated at 3% in Western Europe and 
67% to 90% in tropical countries. Transmission is 
mainly by ingestion of tissue cysts in raw and 
undercooked meat, exposure to oocysts in 
contaminated vegetable or contact with faeces of a 
felid (2).The development of a cell-mediated 
immunity after an acute infection results in the 
control of the disease, but not the eradication of the 
infection. The issuing of a chronic or latent phase of 
infection is characterized by the presence of the 
persistence form (cysts) of the organism in tissues 
(skeletal muscles, heart and brain). An infected 
individual who develops a defective cell-mediated 
immunity is at risk of reactivated infection (1, 2, 3). 
In Cameroon such data are scarce, and information 
used is usually from developed countries. This 
study was therefore carried out to determine the 
sero-prevalence of T. gondii among HIV/AIDS 
patients to help guide health care providers 
initiating treatment. 
MATERIALS AND METHODS 
 Study Area 
 
 
This study was carried out at the University 
Teaching Hospital in Yaoundé (UTHY), located in  
the Central Region of Cameroon. Yaoundé is the 
political capital of Cameroon; with a cosmopolitan 
population of 3,098,044 (~16%) inhabitants of a total 
population of 19,406,100 peoples. The town 
therefore attracts people from all regions of the 
country. The University Teaching Hospital (UTH) 
Yaoundé, where the study was conducted is one of 
the 4 reference hospitals in Yaoundé, which handles 
the diagnosis, treatment and management of many 
diseases including toxoplasmosis and HIV/AIDS.  
 
Study Population and Sample Collection 
This study was carried out from February 2010 to 
May, 2010. We used volunteer patients already 
diagnosed and confirmed to be HIV positive. 
Written informed consent forms were distributed to 
the participants one week prior to the beginning of 
the samples collection. Only HIV positive 
volunteers who returned their informed consent 
forms duly signed were recruited irrespective of 
their gender or clinical state of the disease. All age 
groups were recruited in the study. We collected at 
least 2ml of venous blood from each patient. The 
samples were then centrifuged after the blood had 
clotted to obtain serum that was collected into 
serum-tubes and stored in the freezer for at most 





from 8 am to 1pm and sample processing was done 




The ELISA technique was employed to estimate the 
levels of toxoplasma IgG and IgM antibodies in 
patients’ sera collected. Toxoplasma gondii antibody 
enzyme ELISA kit is a solid phase enzyme-linked 
immune-sorbent assay (ELISA). The ELISA method 
relies basically on the formation of an antigen-
antibody complex, on which an enzyme conjugate 
binds and then reacts with a substrate that is 
detectable by the ELISA machine. Therefore if a 
patient has toxoplasma antibodies, they will bind 
on the antigens coated on the walls of the micro-
wells. The intensity of the reaction between a 
substrate and the conjugate enzyme is reflective of 
the degree of the formation of the antigen-antibody 
complex and hence, estimates qualitative and 
quantitative toxoplasma antibodies in the patient’s 
serum. The procedure was carried out as described 
by Calderaro et al.(4) 
 
Reporting Results 
The ELISA gives results in terms of absorbance 
(optic density). The values of IgM and IgG are 
calculated using a calibration curve converted in 
the standard international units/ml (IU/ml).  
For IgG values  > 73IU/ml positive 
   = 60 to 73 IU/ml 
equivocal 
   < 60 IU/ml negative 
For IgM values > 37 IU/ml positive 
   = 30-37 IU/ml Equivocal 
   < 30 IU/ml negative 
 Statistical Analyses 
The Chi-Square test was used to test the association 
between patient characteristics of the sample 
population and Toxoplasma gondii sero-positivity 
data. A confidence level of 95% was chosen (P-
value = 0.05) and values of chi-square computed 
using Yates correction. 
RESULTS 
A total of 133 immune compromised (HIV/AIDS) 
patients participated in this sero-survey. Ninety 
three (69.9%) of the patients were sero-positive for 
toxoplasma-antibodies and 40 (29.1%) were sero-
negative. Fourteen (10.8%) of the 93 (69.9%) of the 
sero-positive patients presented with both IgG and 
IgM-antibodies in their sera. Fifty six (42.1%) and 8 
(6.0%) were only sero-positive for toxoplasma IgG 
or IgM-antibodies respectively. Seven (5.2%) were 
sero-positive for IgG-antibodies and ambiguous in 
IgM titers, and 2 (1.5%) were only sero-positive for 
IgM-antibodies and ambiguous for toxoplasma 
IgG-antibodies. Three (2.3%) were serologically 
ambiguous for both toxoplasma IgG- and IgM 
titers. Two (1.5%) were serologically ambiguous for 
toxoplasma IgG-antibodies and negative for IgM 
while 1 (0.7%) was ambiguous for IgM and negative 
for IgG antibodies (Table 1). 
From the 93 positive patient samples analyzed, 119 
positive titers where obtained. 77 (64.7%) and 7 
(5.9%) IgG titers were fully established and 
ambiguous respectively, and 24 (20.2%) and 11 
(9.2%) IgM titers were fully established and 
ambiguous respectively. The data provided a P-
value > 0.5 (table2). 
Of the 133 HIV/AIDS patients that participated in 
the human sero-survey, 83 (62.4%) were females 
and 50 (37.6%) were males. Fifty nine (71.1%) of the 
83 (62.4%) females and 34 (68.0) of the 50 (37.6%) 
males were sero-positive for Toxoplasma-
antibodies (Table 3).  
The age of the studied population ranged from 17 
to 55 years of age. The data was categorized into 8 
ranges with a class width of 4. The modal class was 
26 – 30 years of age, with a frequency of 39 (29.3%) 
and an observed sero-positivity frequency of 32 
(24.1%) (P<0.05) (Table 4).  
 
TABLE 1: TOXOPLASMA ANTIBODIES IN HIV/AIDS PATIENTS AT THE UNIVERSITY HOSPITAL YAOUNDÉ 
 














Positive 14 (10.52) 2  (1.50) 8  (6.01) 24 (18.04) 
Equivocal 7(5.26) 3 (2.25) 1 (0.75) 11 (8.27) 
     
Negative 56 (42.10) 2 (1.50) 40  (30.07) 98  (73.78) 
Total 77 (57.89) 7(5.26) 49 (36.84) 133 (100.00) 
 
 
     
  
 
TABLE 2: DISCRIMINATIVE DISTRIBUTION OF 










IgG 77  (64.70) 7 (5.88) 84  (70.58) 
IgM 24 (20.16) 11 (9.24) 35  (29.41) 
Total 101 (84.87) 18  (15.12) 119  (100) 
Df = 1  P-value = 0.05 X2 = 9.81   
 
TABLE 3: DISTRIBUTION OF OXOPLASMA  








Male 34 (25.56) 16 (12.03) 50  (37.59) 
Female 59  (44.36) 24 (18.04) 83  (62.40) 
Total 93 (69.92) 40 (30.07) 133 
(100.00) 











TABLE 4: DISTRIBUTION OF TOXOPLASMA  
SERO-POSITIVITY ACCORDING TO VARIOUS AGE 
RANGES 
 






16 – 20 1 (0.75) 
 
4(3.01) 5(3.76) 
21 – 25 23 (17.29) 
 
14(10.53) 37(27.82) 
26 – 30 32 (24.06) 
 
7(5.26) 39(29.32) 
31 – 35 17 (12.78) 
 
6(4.51) () 23(17.29) 
36 – 40 13(9.77) 
 
2(1.50) 15(11.28) 





46 – 50 1(0.75) 4(3.01) 
 
5(3.76) 
51 – 55 1(0.75) 0 (0.00) 1(0.75) 
Total 93 (69.92) 40(30.08) 133 (100.00) 
Df = 7 P-value = 0.05    X2 = 11.49   
 
DISCUSSION 
The T. gondii seroprevalence estimated for human 
population varies greatly among different countries, 
among different geographical areas within the same 
country, and among different ethnic groups living in 
the same area (5). In this study the prevalence of 
Toxoplasma gondii antibodies in an HIV-positive 
population at the UTHC Yaoundé was found to be 
69.9%. This figure does not differ much from that 
obtained in other African countries : 75.4% in Nigeria 
(6), 60% from AIDS patients in Cote d’Ivoire (7), 
58.4% in Tunisia (8), 53.6% in Benin (9), 40.2% in 
Senegal (10), 34.1% from pregnant women in Sudan 
(11), and 28.5%  in HIV positive women in Benin (5)                     
and confirms the geographical variation. The absence 
of prevention strategies on serious risks of acquiring 
primary infection during pregnancy in these countries 
may account for these important prevalence values. 
In Cameroon, a similar study carried in 1992 (12), 
revealed a toxoplasmosis sero-prevalence of 77.1% in 
pregnant women. The difference in the sero-
prevalence of toxoplasmosis obtained in this study 
can be associated to the fact that in some HIV/AIDS 
patients, the failing immune system may not produce 
detectable amounts of antibodies, hence may account  
for a low sero-prevalence in the sample. Recently, 
highly active antiretroviral therapy (HAART) against 
HIV infection has been advocated for improving the 
immune status of patients thus reducing the incidence 
of opportunistic infections (13); The studied 
population was on antiretroviral treatment regimens 
thank to the implementation of a national 
decentralization programme for HIV care in 2006 that 
led to existing health infrastructures being 
overwhelmed by a huge demand for treatment (14). 
This could explain the fact that most patients with 
antibodies presented with no clinical symptoms of the 
disease. However non-adherence remains a major 
concern as the antiretroviral treatment (ART) 
programs scale up and as more patients are expected 
to remain on this life-long therapy, this necessitates 
the need for the development of additional 
interventions to maintain optimal adherence to ART 
and consequently to reduce patients’ vulnerability to 
opportunistic infections (15). The particular clonal 
lineage may be different compared to the rest of the 
continent and the world. However, studies by 
Lindström et al. (16) described the genotype 
distribution in Uganda to be very similar to that in 
Europe, where type II allele of SAG2-locus was the 
most common. As compared to other areas (Uganda 
where the prevalence was 80%), this area presents a 
better socio-economic condition, rapid urbanization, 
improved access to potable water and sanitation 




time, continued awareness around good hygiene, 
education and rare exposure to stray cats are 
characteristics of the Yaoundé region. The global 
variation in prevalence may also be attributed to 
different cultural habits. The high prevalence has 
been linked to the practice of Buddhism in Thailand 
which has significantly led to the increase in amount 
of stray cats, hence increased possibility of human 
infection (13). In Mexico and Brazil, cats are fed with 
raw viscera and leftover, increasing the chance of 
human infection (17). A 64.7% IgG to 20.2% IgM titer 
provide enough statistical evidence to conclude that 
there is a 95% possibility of any random patient of 
presenting with at least a high IgG titer for 
toxoplasma antibodies. This can be surely attached to 
their failing immune system increasing the patient’s 
vulnerability and the fact that IgG-antibodies last 
longer than IgM-antibodies. It is therefore possible 
most of the toxoplasmosis cases in HIV/AIDS are due 
to a reactivated infection (18). A 3/5 ratio of male to 
females (p>0.05) did not provide enough statistic 
evidence that positivity of toxoplasma antibodies is 
not sex dependent. Hence, any random gender with 
equal risk behaviors can be positive or negative. The 
modal class in this study was within the range of 26 to  
 
30 years of age and could be due to the fact that this 
age group constitute the most active part of a 
population and are therefore exposed to many risk 
factors. However, the statistics did not provide 
enough evidence to incriminate a particular 




This human sero-survey has shown the presence of 
toxoplasmosis amongst HIV/AIDS patients at 
UTHCY, with a prevalence of 69.9%. This infection 
rate does not depend on the patient’s sex or age. The 
data also provide enough evidence to conclude that 
64.7% of the positive cases are due to reactivated 
infections. Pregnant women and immune-
compromised patients should be screened for 
previous Toxoplasma gondii exposure to ensure 
adequate clinical and individual precautions to 
prevent an acute or a reactivated infection.  
 
ACKONOLEDGEMENTS 
The authors wish to thank all the laboratory 
personnel of the University Teaching Hospital of 





1 Tenter A. M., Heckeroth A. R., Weiss L. M. 
Toxoplasma gondii: from animals to humans. 
Intern. J.     Parasitol. 2000; 30: 1217-1258. 
2. Montoya J. G., Rosso F. Diagnosis and 
management of toxoplasmosis. Clin 
Perinatol. 2000; 32: 705-726. 
3.  Luft B. J., Remington J. S. Toxoplasmic 
encephalitis in AIDS. Cli Infect Dis. 1992; 15: 
211-222.  
4.  Calderaro A, Piccolo G, Peruzzi S,  Gorrini 
C,  Chezzi C and Dettori G. Evaluation 
of Toxoplasma gondii Immunoglobulin G 
(IgG) and IgM Assays Incorporating the 
New Vidia Analyzer System. Clin. Vacc. 
Immunol, July 2008, p. 1076-1079, Vol. 15, 
No. 7  
5. Simpore J., Savadogo A., Ilboudo D., 
Nadambega M. C., Esposito M., Yara J., 
Pignatelli S., Pietra V., Musumeci S. 
Toxoplasma gondii, HCV, and HBV 
seroprevalence and co-infection among HIV-
positive and - negative pregnant women in 
Burkina Faso. J Med Virol. 2006; 78:730–733. 
6. Onadeko M. O., Joynson D. H., Payne R. A, 
Francis J. The prevalence of Toxoplasma 
antibodies in pregnant Nigerian women and 
the occurrence of stillbirth and congenital 
malformation. Afr. J. Med. Sci.1996; 25:331–
334. 
7. Adou-Bryn K. D, Ouhon J., Nemer J., Yapo 
C. G., Assoumou A. Serological survey of 
acquired toxoplasmosis in women of 
childbearing age in Yopougon (Abidjan, 
Cote d’Ivoire).  Bull. Soc. Pathol. Exot. 2004; 
97:345–348. 
8. Bouratbine A., Siala E., Chahed M. K., Aoun 
K., Ben Ismail R. Seroepidemiologic profile 
of toxoplasmosis in Northern Tunisia. 
Parasite Immunol. 2001; 8:61–66. 
9. Rodier M. H., Berthonneau J., Bourgoin A., 
Giraudeau G., Agius G., Burucoa C., 
Kekpazo A., Jacquemin J. L. Sero-
prevalences of toxoplasma, malaria, rubella, 
cytomegalovirus, HIV and treponemal 
infections among pregnant women in 
Cotonou. Repub. Benin. Acta Trop. 1995; 
59:271-277.  
10.  Faye O., Leye A., Dieng Y., Richard-Lenoble 
D., Diallo S. Toxoplasmosis in Dakar. 
Seroepidemiologic sampling of 353 women 
of reproductive age. Bull. Soc. Pathol. Exot. 
1998; 91:249–250. 11.  Elnahas A., 
Gerais A. S, Elbashir M.I, Eldien E. S., Adam 
I. Toxoplasmosis in pregnant Sudanese 




12.  Ndumbe P. M., Andela A., Nkemnkeng-
Asong J., Watonsi E., Nyambi P. Prevalence 
of infections affecting the child among 
pregnant women in Yaoundé, Cameroon. 
Med. Microbiol. Immunol. 1992; 181:127-130.  
13.  Sukthana Y., Chintana T., Supathanapong 
W., Siripanth C., Lekkla A., Chiabchalard R. 
Prevalence of toxoplasmosis in Selected 
Populations in Thailand. J Trop Med 
Parasitol 2000;23:53-58 
14.  MOH (Ministry of Public Health). National 
strategy plan to fight against HIV/AIDS. 
National Committee to FightAIDS, 
Cameroon. 2006-2010,Yaounde, Cameroon. 
2009 
15.  Kamga H. L. F., Assob J. C. N., Njunda A. L, 
Nsagha D. S., Nde Fon P., Atanga M. B. 
S.,  Weledji P., Achidi E. A. Puinta D. P. The 
kidney function trends in HIV/AIDS 
patients. Lambert Academic Publishing, 
Germany. 2011 
16.  Lindström I., Kaddu-Mulindwa D., Kironde 
F., Lindh J. Prevalence of  latent and 
reactivated Toxoplasma gondii parasites in 
HIV-patients from Uganda. Acta Trop. 2006; 
100: 218-222. 
17.    Sukthana, Y. Toxoplasmosis: beyond animals 
to humans. Trends Parasitol., 2006; 22:137-
142 
18.  Rougemont M., Stoll B. E, Elia N., and 
Ngang P. Antiretroviral treatment and its 
determinants in sub-Saharan Africa: a 
prospective study at the Yaounde Central 
Hospital, Cameroon. AIDS Res. Ther. 2009; 
6:21.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
 
